Invizyne Technologies Inc(IZTC) - 2025 Q1 - Quarterly Report

Financial Performance - The company reported a net loss of $1,856,421 for the three months ended March 31, 2025, compared to a net loss of$1,008,458 for the same period in 2024, indicating an increase in losses of approximately 84.2%[11] - Basic and diluted loss per share for the three months ended March 31, 2025, was $(0.22), compared to$(0.16) for the same period in 2024[61] - The net loss for the three months ended March 31, 2025, was $1,856,421, compared to a net loss of$1,008,458 for the same period in 2024[11] - The company experienced a net cash decrease of $(1,207,833) during the three months ended March 31, 2025, compared to an increase of$47,263 in the same period of 2024[21] Assets and Liabilities - Total assets decreased from $13,034,404 on December 31, 2024, to$11,525,692 on March 31, 2025, representing a decline of approximately 11.5%[9] - Cash and cash equivalents decreased from $9,719,310 at the beginning of the period to$8,511,477 at the end of the period, a reduction of approximately 12.4%[16] - The Company had cash equivalents of $8,159,472 as of March 31, 2025, with approximately$8,186,086 in cash exceeding FDIC insurance limits[31][32] - The Company reported right-of-use assets of $1,263,855 and operating lease liabilities of$1,326,424[79] - The total future payments due under operating leases as of March 31, 2025, amount to $1,560,636, with the largest payment of$378,576 due in 2028[81] Operating Costs - Total operating costs increased to $1,950,728 in Q1 2025 from$1,008,458 in Q1 2024, reflecting a rise of approximately 93.3%[11] - Cash used in operating activities was $(1,133,533) for the three months ended March 31, 2025, compared to cash provided of$281,199 in the same period of 2024, indicating a significant decline in operational cash flow[21] - Stock-based compensation for the three months ended March 31, 2025, was $317,277, compared to$142,810 for the same period in 2024[53] Research and Development - Research and development costs net of grants amounted to $575,016 for Q1 2025, up from$277,582 in Q1 2024, marking an increase of approximately 107.2%[11] - Research and development costs for the three months ended March 31, 2025, amounted to $1,150,797, compared to$986,282 for the same period in 2024, reflecting an increase of approximately 16.6%[40] - The Company received grant reimbursements of $571,822 and$674,158 for research and development costs for the three months ended March 31, 2025, and 2024, respectively[39] Shareholder Information - The weighted average number of common shares outstanding increased from 6,250,002 in Q1 2024 to 8,367,810 in Q1 2025, reflecting a growth of approximately 33.9%[11] - The Company has a total of 1,747,789 stock options outstanding as of March 31, 2025, with a weighted average remaining contractual life of 5.54 years[54] - As of March 31, 2025, stock options to purchase 632,757 shares of Common Stock were vested, with a weighted average exercise price of $4.57[53] Legal and Compliance - The company has not recorded any accrued royalties under the exclusive license agreement as of March 31, 2025[68] - The company has met all development milestones required under the license agreement as of March 31, 2025[69] - The company is classified as an "emerging growth company," allowing it to take advantage of certain exemptions from various reporting requirements[24] Subsidiaries and Ventures - The company established a wholly owned subsidiary, NCTx LLC, focused on developing a rare plant-derived compound relevant to metabolic health[82] - The company has filed a provisional patent application for deuterated cannabinoid molecules in a joint venture with Neuractas Therapeutics, although no business activities have occurred to date[19] Funding and Grants - The Company has a minority interest of 48$595,160 as of March 31, 2025, down from $1,111,611 at the end of March 2024, indicating a decrease of approximately 46.5%[39]